Wednesday, February 10, 2010, 6:49pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Allos Therapeutics, Inc. (ALTH)

At 5:00AM SGT: 6.94 USD   0.00 (0.00%)  
 MORE ON ALTH 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Allos Therapeutics, Inc. (NGM:ALTH) Delayed quote dataEdit
Last Trade:6.94 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:6.94
Open:N/A
Bid:N/A
Ask:8.02 x 1000
1y Target Est:11.94
Day's Range:N/A - N/A
52wk Range:5.34 - 8.79
Volume:0
Avg Vol (3m):1,740,830
Market Cap:721.35M
P/E (ttm):N/A
EPS (ttm):-0.77
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ALTH to Portfolio   Download Data

 HEADLINES 
•Dow plummets; Kodiak Oil down 9%; Allos, Golden Star down 8%
at bizjournals.com (Fri, Feb 5)
•10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
•Allos Therapeutics to Present at BIO CEO & Investor Conference
Business Wire (Wed, Feb 3)
•Cell Therapeutics' Upcoming FDA Worries
at TheStreet.com (Mon, Feb 1)
•Cramer's 'Mad Money' Follow-Up: Jan. 27
at TheStreet.com (Thu, Jan 28)
•Mad Mail: Is Chipotle Mexican Grill a Buy?
at CNBC (Wed, Jan 27)
•Dow off a few points; Vail Resorts, Delta Petroleum up 5%
at bizjournals.com (Wed, Jan 27)
•Dow halts slide; Liberty Global up 8%, Delta Petroleum up 7%
at bizjournals.com (Tue, Jan 26)
•Stock Smackdown: Cramer vs. CAPS
at Motley Fool (Tue, Jan 26)
•Dow continues to seesaw; Delta Petroleum leads Colorado gainers
at bizjournals.com (Thu, Jan 21)
More Headlines for ALTH...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.78
EPS Est (in 2 years) (Dec-10) :-0.42
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumula...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices